Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

2.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.7K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

10.5K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.5K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Structure and Function of Platelets01:18

Structure and Function of Platelets

4.5K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
4.5K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

589
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
589

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Von Willebrand disease: A century of progress.

Research and practice in thrombosis and haemostasis·2026
Same author

Murine Models of Hemostasis: How to Assess Bleeding in Mice and Clinical Relevance of These Models for Testing New Therapeutics.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same author

Novel therapies for von Willebrand Disease.

Blood advances·2026
Same author

Factor X colocalizes with amyloid light chain deposits in AL amyloidosis: evidence from three patients.

Haematologica·2026
Same author

Fitusiran treatment modulates the ratio between alpha- and beta-antithrombin isoforms.

HemaSphere·2026
Same author

A scalable high-throughput platform for the discovery of intracellular and extracellular regulators of platelet migration.

Blood advances·2026
Same journal

Apoptotic versus procoagulant platelets: similar "necrotic" phenotype and procoagulant activity in vitro, but distinct adhesive protein composition.

Thrombosis research·2026
Same journal

Heatstroke-induced coagulopathy: A scoping review of therapeutic strategies and outcome reporting.

Thrombosis research·2026
Same journal

Mapping thrombus habitat: Non-contrast MRI radiomics and pixel-tile histomics approach to track venous thrombosis evolution in mice.

Thrombosis research·2026
Same journal

A study protocol for a randomised controlled trial evaluating the safety and efficiency of the YEARS algorithm versus computed tomography pulmonary angiography only for suspected acute pulmonary embolism in patients with cancer: the Hydra Study.

Thrombosis research·2026
Same journal

Associating the phenotypic expression of platelets with disease type through image-based single-cell profiling.

Thrombosis research·2026
Same journal

The mechanisms of contractile dysfunction following chronic limited platelet activation in (pro)thrombotic conditions.

Thrombosis research·2026
See all related articles

Related Experiment Video

Updated: Mar 20, 2026

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

1.2K

Acquired platelet disorders.

Caterina Casari1, Wolfgang Bergmeier2

  • 1McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Thrombosis Research
|May 22, 2016
PubMed
Summary
This summary is machine-generated.

Acquired platelet dysfunction, often caused by medications or diseases, is more common than congenital disorders. Understanding the molecular basis of these conditions, especially in von Willebrand disease, is crucial for improving patient care.

Keywords:
acquireddiseasedysfunctionhemostasisplateletssignaling

More Related Videos

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K
Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

1.3K

Related Experiment Videos

Last Updated: Mar 20, 2026

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

1.2K
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K
Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

1.3K

Area of Science:

  • Hematology
  • Molecular Biology
  • Clinical Medicine

Background:

  • Acquired platelet dysfunction is more prevalent than congenital platelet disorders in clinical settings.
  • Medications and systemic or hematologic diseases are primary causes of acquired platelet dysfunction.
  • Clinical signs include mucosal bleeding, epistaxis, and superficial epidermal bleeding, typically mild.

Purpose of the Study:

  • To provide an overview of acquired platelet disorders.
  • To highlight recent mechanistic studies on platelet dysfunction.
  • To focus on platelet dysfunction in von Willebrand disease.

Main Methods:

  • Literature review of acquired platelet disorders.
  • Analysis of recent mechanistic studies.
  • Focus on molecular mechanisms of platelet dysfunction in von Willebrand disease.

Main Results:

  • Acquired platelet dysfunctions are common and multifactorial.
  • Molecular mechanisms are often not fully understood.
  • Recent studies offer insights into platelet dysfunction in specific conditions like von Willebrand disease.

Conclusions:

  • Acquired platelet disorders require further mechanistic investigation.
  • Improved understanding can lead to optimized patient management.
  • Focusing on conditions like von Willebrand disease is key to advancing care.